To analyze the expression levels of CD46 in glioma patients, we conducted an analysis using the Cancer Genome Atlas Program (TCGA) database and single-cell data (GSE131928) as depicted in Fig. 3A. As shown in Fig. 3B, CD46 is highly expressed in tumor tissues of multiple cancer types, according to a pan-cancer analysis of the TCGA database, indicating that CD46 may serve as an oncogenic target across various cancer types. Here, CD46 is linked to central nervous system cancer.